TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
TAG stands proudly alongside the TB community to issue this press statement calling for increasing European funding for TB vaccine development, just before the sixth Global Forum on TB Vaccines convenes in Toulouse, France.
On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2020 and analyzes trends in funding since 2005.
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.